CHMP turns down antisense compound citing safety issues

The Committee for Medicinal Products for Human Use has turned down an application from  Genzyme (Sanofi) to market an antisense compound for familial hypercholesterolaemia citing safety concerns. Genzyme said it will appeal against the opinion.